NCT02992912View on ClinicalTrials.gov

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

May 20, 2022

Study Completion Date

October 31, 2024

Conditions
Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
Interventions
DRUG

Anti-PD-L1 antibody atezolizumab

1200 mg every 3 weeks

PROCEDURE

SABR

Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER